WO2005043121A3 - Blood test prototypes and methods for the detection of circulating tumor and endothelial cells - Google Patents

Blood test prototypes and methods for the detection of circulating tumor and endothelial cells Download PDF

Info

Publication number
WO2005043121A3
WO2005043121A3 PCT/US2004/036177 US2004036177W WO2005043121A3 WO 2005043121 A3 WO2005043121 A3 WO 2005043121A3 US 2004036177 W US2004036177 W US 2004036177W WO 2005043121 A3 WO2005043121 A3 WO 2005043121A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cells
fetal
cardiovascular
metastatic
Prior art date
Application number
PCT/US2004/036177
Other languages
French (fr)
Other versions
WO2005043121A2 (en
Inventor
Wen-Tien Chen
Lee Chen
Che Chen
Original Assignee
Vitatex Inc
Wen-Tien Chen
Lee Chen
Che Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitatex Inc, Wen-Tien Chen, Lee Chen, Che Chen filed Critical Vitatex Inc
Priority to EP04796843A priority Critical patent/EP1706720A4/en
Priority to AU2004286307A priority patent/AU2004286307A1/en
Priority to JP2006538370A priority patent/JP2007526761A/en
Priority to CA002544373A priority patent/CA2544373A1/en
Publication of WO2005043121A2 publication Critical patent/WO2005043121A2/en
Publication of WO2005043121A3 publication Critical patent/WO2005043121A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5082—Test tubes per se
    • B01L3/50825—Closing or opening means, corks, bungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/04—Cell isolation or sorting
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/04—Closures and closing means
    • B01L2300/046—Function or devices integrated in the closure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Abstract

Methods and devices for isolating and diagnosing disease with a cell adhesion matrix system, mimicking a metastatic, cardiovascular or placental environment, are disclosed. The cell adhesion matrix facilitates the enrichment of target cells such as metastatic tumor cells, fetal cells and endothelial progenitor cells from a fluid sample such as blood for diagnostic and therapeutic application s in treating patients afflicted with disease, such as cancerous, cardiovascular and fetal diseases, as well as for research applications in molecular analysis of metastatic, and cardiovascular and fetal diseases. Blood test prototypes and methods for the cell enrichment and detection of circulating tumor and endothelial cells using multiplex molecular analysis are described herein. In addition, methods and compositions for determining host immunity to tumor in subjects with risk of cancer progression and methods for isolating an enriched fraction of fetal cells from pregnant females for prenatal diagnosis are also described herein.
PCT/US2004/036177 2003-10-31 2004-10-30 Blood test prototypes and methods for the detection of circulating tumor and endothelial cells WO2005043121A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04796843A EP1706720A4 (en) 2003-10-31 2004-10-30 Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
AU2004286307A AU2004286307A1 (en) 2003-10-31 2004-10-30 Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
JP2006538370A JP2007526761A (en) 2003-10-31 2004-10-30 Blood test prototypes and methods for the detection of circulating tumor cells and endothelial cells
CA002544373A CA2544373A1 (en) 2003-10-31 2004-10-30 Blood test prototypes and methods for the detection of circulating tumor and endothelial cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51657103P 2003-10-31 2003-10-31
US60/516,571 2003-10-31

Publications (2)

Publication Number Publication Date
WO2005043121A2 WO2005043121A2 (en) 2005-05-12
WO2005043121A3 true WO2005043121A3 (en) 2006-08-24

Family

ID=34549552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036177 WO2005043121A2 (en) 2003-10-31 2004-10-30 Blood test prototypes and methods for the detection of circulating tumor and endothelial cells

Country Status (7)

Country Link
EP (1) EP1706720A4 (en)
JP (1) JP2007526761A (en)
CN (2) CN1922304A (en)
AU (1) AU2004286307A1 (en)
CA (1) CA2544373A1 (en)
HK (1) HK1209778A1 (en)
WO (1) WO2005043121A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8986966B2 (en) 2002-09-27 2015-03-24 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US9174222B2 (en) 2005-04-05 2015-11-03 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913697B2 (en) 2001-02-14 2005-07-05 Science & Technology Corporation @ Unm Nanostructured separation and analysis devices for biological membranes
US7910315B2 (en) 2004-09-10 2011-03-22 The Regents Of The University Of Colorado, A Body Corporate Early detection of hemangiosarcoma and angiosarcoma
US7769547B2 (en) * 2005-11-01 2010-08-03 David S. Alberts Karyometry-based method for prediction of cancer event recurrence
WO2007121464A2 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of circulating endothelial cells
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US20080070792A1 (en) 2006-06-14 2008-03-20 Roland Stoughton Use of highly parallel snp genotyping for fetal diagnosis
EP1867995A1 (en) * 2006-06-15 2007-12-19 Cézanne S.A.S. In vitro method for diagnosing and monitoring metastasized bladder cancer using the determination of MMP-7 in the circulation of patients
BRPI0820793A2 (en) 2007-12-10 2015-06-16 Hoffmann La Roche Seprase as a cancer marker
ITCZ20090001A1 (en) * 2009-01-13 2010-07-14 Natalia Malara ISOLATION AND CULTIVATION OF TUMORAL EPITHELIAL CELLS FROM THE BLOOD AND ITS DERIVATIVES IN PATIENTS WITH SOLID EPITHELIAL CANCER
EP2363501A1 (en) * 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
CN102213722B (en) * 2010-04-06 2014-03-12 北京蛋白质组研究中心 Application of kit for detecting protein expression level in preparation of kit for diagnosing hepatocellular carcinoma
CA2805586C (en) 2010-07-16 2020-09-01 Stichting Vu-Vumc A method of analysing a blood sample of a subject for the presence of a disease marker
AU2012231884B2 (en) 2011-03-18 2017-03-09 Stichting Vumc A method of analysing a blood sample of a subject for the presence of a disease marker
CA2839313C (en) * 2011-06-13 2018-03-13 Hitachi Chemical Company, Ltd. Agent for improving cancer cell adhesiveness
MX2014000095A (en) * 2011-07-07 2014-05-28 Janssen Diagnostics Llc Method of analyzing cardiovascular disorders and uses thereof.
CA2841173C (en) 2011-07-08 2022-06-21 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
JP5834559B2 (en) * 2011-07-12 2015-12-24 コニカミノルタ株式会社 Target cell inspection method
JP6208473B2 (en) 2012-06-20 2017-10-04 アークレイ株式会社 Method for processing samples containing blood components
CA2891028C (en) 2012-11-09 2017-02-07 F. Hoffmann-La Roche Ag In vitro capture and analysis of circulating tumor cells
CN105122031B (en) * 2012-11-20 2019-02-01 纽约哥伦比亚大学董事会 Medical Devices and method for collecting biological sample
GB2546213B (en) * 2013-02-02 2017-12-06 Univ Duke Method of isolating circulating tumour cells
JP6052756B2 (en) * 2014-07-22 2016-12-27 株式会社がん免疫研究所 Peripheral circulating cancer cell detection method and detection apparatus
SG10201804421XA (en) * 2015-01-21 2018-07-30 Agency Science Tech & Res Column-based device and method for retrieval of rare cells based on size, and uses thereof
JP6901253B2 (en) * 2015-10-21 2021-07-14 株式会社日本触媒 Adhesive cell culture substrate, cell culture container and cell culture method using this
CN105420088B (en) * 2015-11-11 2017-12-29 深圳市达科为生物工程有限公司 A kind of cell Separating tube
EP3378945B1 (en) * 2015-12-14 2021-04-28 Quanta Matrix Co., Ltd. Method for distinguishing particular cells from mixture of heterogeneous cells
JP6518985B2 (en) * 2016-09-29 2019-05-29 住友ゴム工業株式会社 Cancer cell capture method
SG11201901782TA (en) * 2016-11-02 2019-05-30 Emd Millipore Corp Container for separating microcarriers from cell culture fluids
AU2017379367B2 (en) 2016-12-20 2023-12-07 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors
CN108220233B (en) * 2016-12-21 2021-07-09 上海透景诊断科技有限公司 Cell separation instrument surface treatment method, related instrument, and method for rapidly and efficiently separating peripheral blood rare cells or circulating tumor cells
EP3342485B1 (en) * 2017-01-02 2020-07-08 Thinxxs Microtechnology Ag Holder for reagent elements
CN106754650B (en) * 2017-02-24 2018-10-02 哈尔滨中科赛恩斯生物技术有限公司 A kind of endothelial progenitor cells cultural method of derived from bone marrow
CN106840816A (en) * 2017-03-14 2017-06-13 骏实生物科技(上海)有限公司 A kind of Full-automatic circulation tumour cell feminine gender enriching apparatus
KR102583603B1 (en) * 2017-03-16 2023-10-05 유니베르시테 리브레 드 브룩크젤즈 Detection, quantification and/or isolation of circulating tumor cells based on expression of the CD321 marker
WO2019023961A1 (en) * 2017-08-02 2019-02-07 Suzhou Bofu Biomedical Limited Method for capturing target cells or molecules in solution
US20200156073A1 (en) * 2017-08-02 2020-05-21 Hemosmart Medical Technology Ltd. Functionalized mesh and fluidic apparatus for capturing cells or molecules in solution
CN108031614B (en) * 2017-12-14 2020-04-17 四川福德机器人股份有限公司 Automatic glue coating compensation method for gas meter and device adopting same
BR112020020083A2 (en) * 2018-03-30 2021-01-05 Exosomics S.P.A IN VITRO USE OF HOLY FIBERS, IN VITRO METHOD FOR OBTAINING BLOOD OR A BLOOD DERIVATIVE AND IN VITRO METHOD FOR ANALYZING THE CONTENT OF EXTRACELLULAR VESICLES FROM BLOOD OR BLOOD DERIVED FROM BLOOD
CN109294973A (en) * 2018-10-18 2019-02-01 重庆医科大学 A method of blood urine enriched for leukemic cells epithelial cell is removed based on paramagnetic particle method feminine gender
CN109887542A (en) * 2019-02-12 2019-06-14 嘉兴海云惠智医疗科技有限公司 A kind of tumour individuation genetic test intelligence solution read apparatus based on cloud computing
CN111751543A (en) * 2019-03-27 2020-10-09 南方医科大学南方医院 Rare tumor cell enrichment method and kit
JP6886667B2 (en) * 2019-03-27 2021-06-16 住友ゴム工業株式会社 Cancer cell capture method
CN111235021B (en) * 2020-03-06 2022-09-27 大连海事大学 Double-liquid-phase separation and detection device and method for circulating tumor cells in peripheral blood
CN112255408B (en) * 2020-10-16 2023-04-14 牡丹江医学院 Tumor biomarker and tumor detection kit
CN113117359B (en) * 2021-03-05 2022-08-26 湘雅生物医药(湖州)有限公司 A aseptic formula retort for collagen draws usefulness
CN113049344B (en) * 2021-04-20 2022-02-01 深圳天烁生物科技有限公司 Preparation method of quality control product for cell staining

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5840514A (en) * 1996-11-21 1998-11-24 The Regents Of The University Of Michigan Methods of testing cancer and anticancer drugs
US6060317A (en) * 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092246A (en) * 1975-05-16 1978-05-30 Abcor, Inc. Helically wound blood filter
US5147797A (en) * 1987-08-25 1992-09-15 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
EP0784499A4 (en) * 1992-09-11 2000-03-29 Xenogenex Inc Artificial liver apparatus and method
FI93742C (en) * 1992-10-23 1995-05-26 Elias Hakalehto Method and apparatus for detecting cells
ATE237676T1 (en) * 1995-02-16 2003-05-15 Forschungszentrum Juelich Gmbh METHOD FOR CULTIVATION OF ORGAN FUNCTIONAL CELLS
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
JPH11127843A (en) * 1997-10-27 1999-05-18 Sumitomo Bakelite Co Ltd Colored container for culture
MXPA01002674A (en) * 1998-09-14 2002-06-04 Ostergaard Pedersen Lars A method of producing a functional immunoglobulin superfamily protein.
JP5433840B2 (en) * 2000-09-09 2014-03-05 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク Methods and compositions for isolating metastatic cancer cells and their use in measuring the metastatic potential of cancer
GB0025245D0 (en) * 2000-10-14 2000-11-29 Lee Helen Multiple target detection
CN1118563C (en) * 2000-12-08 2003-08-20 中国医学科学院血液学研究所 Hematopoietic device using hollow fibre to simulate bone marrow
WO2003035888A1 (en) * 2001-08-28 2003-05-01 Wen-Tien Chen Cell separation matrix
EP1409745B1 (en) * 2001-09-06 2007-04-11 Adnagen AG Method and kit for the diagnosis or treatment control of intestinal carcinoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5840514A (en) * 1996-11-21 1998-11-24 The Regents Of The University Of Michigan Methods of testing cancer and anticancer drugs
US6060317A (en) * 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOCKING D. ET AL.: "Activation of Distinct Alpha5Beta - mediated Signaling PAthway by Fibronectin's Cell Adhesion and MAtrix Assembly Domains.", JOURNAL OF CELL BIOLOGY, vol. 141, no. 1, 6 April 1998 (1998-04-06), pages 241 - 253, XP003010319 *
See also references of EP1706720A4 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986966B2 (en) 2002-09-27 2015-03-24 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
US9174222B2 (en) 2005-04-05 2015-11-03 The General Hospital Corporation Devices and method for enrichment and alteration of cells and other particles
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US9017942B2 (en) 2006-06-14 2015-04-28 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US9273355B2 (en) 2006-06-14 2016-03-01 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9347100B2 (en) 2006-06-14 2016-05-24 Gpb Scientific, Llc Rare cell analysis using sample splitting and DNA tags
US8296076B2 (en) 2008-09-20 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuoploidy by sequencing
US8682594B2 (en) 2008-09-20 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9353414B2 (en) 2008-09-20 2016-05-31 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9404157B2 (en) 2008-09-20 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing

Also Published As

Publication number Publication date
HK1209778A1 (en) 2016-04-08
CN1922304A (en) 2007-02-28
JP2007526761A (en) 2007-09-20
EP1706720A2 (en) 2006-10-04
CA2544373A1 (en) 2005-05-12
WO2005043121A2 (en) 2005-05-12
AU2004286307A1 (en) 2005-05-12
CN104531529A (en) 2015-04-22
EP1706720A4 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
WO2005043121A3 (en) Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
WO2006085984A3 (en) Immune cell biosensors and methods of using same
WO2011082345A3 (en) Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
CN105603101B (en) Detect application of the system of 8 miRNA expression quantity in diagnosis or auxiliary diagnosis of hepatoma product is prepared
WO2006104474A3 (en) A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
Myung et al. Integration of biomimicry and nanotechnology for significantly improved detection of circulating tumor cells (CTCs)
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
Liu et al. Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study
WO2009126969A3 (en) Biomarkers for endometrial disease
JP2013514070A (en) Marker of rosacea and diagnostic method
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
JP2016500821A5 (en)
CN103667444B (en) A kind of tumor marker relevant to carcinoma of the pancreas and application thereof
WO2020077341A8 (en) Methods and compositions for identifying and treating subjects at risk for poor car t cell therapy response
WO2006023563A3 (en) A diagnostic imaging device for the analysis of circulating rare cells
Ma et al. Distinct tumor bacterial microbiome in lung adenocarcinomas manifested as radiological subsolid nodules
WO2003069307A3 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
WO2006110768A3 (en) System, method and software arrangement for analyzing and correlating molecular profiles associated with anatomical structures
CN107254546B (en) SNP marker related to breast cancer neoadjuvant chemotherapy curative effect and application thereof
CN107287345B (en) Detection kit for accurate diagnosis and treatment of acute myeloid leukemia and TSEN34 clinical application
Dander et al. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation
WO2002072752A3 (en) Forms of prostate specific antigens and methods for their detection

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480039363.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006538370

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2544373

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004286307

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004286307

Country of ref document: AU

Date of ref document: 20041030

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004286307

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004796843

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004796843

Country of ref document: EP